Bank of America Corp DE Has $47.69 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Bank of America Corp DE increased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 12.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,211,509 shares of the company's stock after acquiring an additional 129,746 shares during the quarter. Bank of America Corp DE owned about 1.42% of CRISPR Therapeutics worth $47,685,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in CRSP. Western Pacific Wealth Management LP increased its holdings in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company's stock worth $39,000 after acquiring an additional 500 shares during the last quarter. Spire Wealth Management grew its holdings in CRISPR Therapeutics by 303.7% in the 4th quarter. Spire Wealth Management now owns 1,970 shares of the company's stock valued at $78,000 after buying an additional 1,482 shares in the last quarter. MCF Advisors LLC acquired a new position in CRISPR Therapeutics in the 4th quarter valued at $80,000. First Horizon Advisors Inc. grew its holdings in CRISPR Therapeutics by 33.4% in the 4th quarter. First Horizon Advisors Inc. now owns 2,039 shares of the company's stock valued at $80,000 after buying an additional 511 shares in the last quarter. Finally, AdvisorNet Financial Inc grew its holdings in CRISPR Therapeutics by 91.1% in the 4th quarter. AdvisorNet Financial Inc now owns 2,478 shares of the company's stock valued at $98,000 after buying an additional 1,181 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded down $0.10 during mid-day trading on Tuesday, reaching $38.58. 362,208 shares of the company were exchanged, compared to its average volume of 1,674,019. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $67.88. The stock has a market capitalization of $3.33 billion, a PE ratio of -8.82 and a beta of 1.88. The business has a 50 day simple moving average of $37.40 and a two-hundred day simple moving average of $42.24.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same period in the prior year, the company earned ($1.43) EPS. CRISPR Therapeutics's revenue for the quarter was up 71.6% compared to the same quarter last year. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the firm's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company's stock, valued at $9,473,037.60. This trade represents a 9.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Julianne Bruno sold 1,198 shares of the firm's stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $50,819.16. Following the sale, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at $350,516.46. This represents a 12.66% decrease in their position. The disclosure for this sale can be found here. Insiders sold 32,381 shares of company stock worth $1,608,243 over the last ninety days. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of research reports. Chardan Capital decreased their price objective on CRISPR Therapeutics from $84.00 to $82.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Evercore ISI raised CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and upped their price objective for the company from $60.00 to $99.00 in a report on Friday, February 14th. HC Wainwright reissued a "buy" rating and set a $65.00 target price on shares of CRISPR Therapeutics in a report on Tuesday. The Goldman Sachs Group reduced their target price on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Finally, Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, CRISPR Therapeutics has a consensus rating of "Hold" and a consensus price target of $71.75.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.